KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Operations (2018 - 2025)

Esperion Therapeutics' Cash from Operations history spans 8 years, with the latest figure at 45243000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 229.44% year-over-year to 45243000.0; the TTM value through Dec 2025 reached 13093000.0, up 44.65%, while the annual FY2025 figure was 13093000.0, 44.65% up from the prior year.
  • Cash from Operations reached 45243000.0 in Q4 2025 per ESPR's latest filing, up from 4286000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 53828000.0 in Q1 2024 to a low of 89068000.0 in Q1 2021.
  • Average Cash from Operations over 5 years is 30543500.0, with a median of 36190500.0 recorded in 2023.
  • The largest YoY upside for Cash from Operations was 229.44% in 2025 against a maximum downside of 336.11% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 57706000.0 in 2021, then rose by 26.4% to 42472000.0 in 2022, then grew by 12.75% to 37056000.0 in 2023, then rose by 5.68% to 34952000.0 in 2024, then skyrocketed by 229.44% to 45243000.0 in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Cash from Operations are 45243000.0 (Q4 2025), 4286000.0 (Q3 2025), and 31422000.0 (Q2 2025).